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reports of effective and cost-conscious HIV
care that can truly be implemented with the
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Prevention and Treatment of HIV/AIDS and Other Infectious
Diseases in Correctional Settings: An Opportunity Not Yet Seized
Theodore M. Hammett, Ph.D.
Abt Associates Inc.

Correctional health care providers manage
the care of a large number of individuals with
communicable diseases in the U.S. A major
portion of the nations Hepatitis B&C, HIV,
STD and TB infected patients pass through
prison and jail doors (see Heppigram).
Moreover, many of these individuals also have
other co-morbid conditions such as psychiatric
illnesses, substance abuse and chronic medical conditions that thwart an integrated care
approach for these patients in community settings.
Within correctional populations, moreover,
women and people of color are much more
heavily affected than men and Caucasian
inmates. For instance, in most geographical
areas, the prevalence of HIV among women
prisoners is twice that found among male prisoners. Similar to findings in communityderived studies, people of color are disproportionately affected by all communicable diseases, however this phenomenon is magnified within our correctional system.
The disproportionately high burden of disease
in correctional institutions identifies an
extremely important opportunity to intervene
aggressively with prevention and treatment
programs. Such interventions promise to benefit not only inmates themselves and their
partners and families, but also the broader
public health. Contrary to popular perception,
correctional facilities are a part of the community. The vast majority of inmates return to our
streets and neighborhoods --more than 8 million are released from jails and prisons per
year -- where they may either continue to
place themselves and others at risk for infectious disease, or help to halt the linked epidemics of disease in the poor, under-served
communities which are home to most of them.
The nation's correctional systems, public
health departments, and community based
providers have not yet exploited this important
public health opportunity, except in a minority
of instances. While there have been improvements in recent years and many correctional
administrators appear to be taking an increasingly enlightened view of health services and

disease prevention, there remains considerable room for improvement. Results of a
series of national surveys of HIV/AIDS, STDs,
and TB in correctional facilities elucidate the
key areas of need.1 Progress and remaining
needs in several key areas are summarized
below.
Substance abuse treatment
The vast majority of correctional inmates have
substance abuse problems. Successful treatment and achievement of permanent sobriety
normally require multiple and prolonged treatment episodes. Periods of incarceration offer
important opportunities to provide substance
abuse treatment and thereby increase exoffenders' chances of resisting relapse and
avoiding recidivism.
Nevertheless, statistics from the Center on
Addiction and Substance Abuse (CASA) at
Columbia University reveal a serious and
growing gap between the number of inmates
needing drug treatment and those receiving
treatment. In 1996, CASA estimated, there
were 840,000 inmates in need of treatment
but only 150,000 (18%) in treatment in correctional facilities.2 Current drug treatment programs are rarely offered to individuals in jails
or who are serving short sentences.
Treatment for HIV Disease
The 1996-1997 CDC/NIJ survey was conducted just as the new antiretroviral therapies
were becoming widely available. The survey
included only a limited number of questions
about HIV treatment. The next round of the
Continued on page 2
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Prevention and Treatment of HIV/AIDS and Other Infectious Diseases in Correctional
Settings: An Opportunity Not Yet Seized
Continued from page 1

survey will examine treatment in greater
detail. The responses to these questions
indicate that the vast majority of state/federal and city/county correctional systems
made protease inhibitors (90%, 93%) and
combination therapy (90%, 90%) available to
inmates. However, these results do not
demonstrate that these therapies were provided to all inmates who should have been
receiving them on an uninterrupted basis.
Indeed, there is anecdotal evidence to suggest that there may be substantial problems
with continuously available medications in at
least some correctional facilities. Nor do the
survey results demonstrate that inmates
were being prescribed the most appropriate
combination therapies. A recent study by
Stadtlanders Pharmacy, which provides
pharmacy services to many correctional systems, found that 52% of about 3,500 inmates
whose pharmacy records were examined
were receiving either "preferred" (45%) or
"alternative" (7%) combinations based on
currently accepted federal guidelines and
more than one third were receiving either
"not generally recommended' (28%) or "not
recommended" (8%) regimens.3 There is
clearly room for improvement in compliance
with the DHHS Guidelines in treating HIVinfected inmates.
HIV/AIDS education and prevention
As of 1997, about two-thirds of correctional
facilities in the U.S. were providing instructor-led HIV/AIDS education, the most basic
ingredient of an education and prevention
program. Moreover, while most HIV education programs covered basic information on
the disease, far fewer included practical risk
reduction information, such as strategies for
negotiating safer sex and methods of safer
injection. Only about a third were providing
more intensive multi-session HIV prevention
counseling programs, the type of program
probably needed to help inmates initiate and
sustain the difficult behavioral changes
required to reduce their risks of acquiring or
transmitting HIV and other infectious diseases. Finally, only 13% of prisons and 3%
of jails were offering peer-based programs in
which inmates provide education and prevention services to other inmates. This represents an extremely under utilized but
promising and potentially very cost-effective

method of providing these services.
One definition of a "comprehensive"
HIV/AIDS education and prevention program
is that all of the following are provided in all
of a correctional system's facilities: instructor-led education; HIV pre- and post-test
counseling; peer-led programs; and multisession prevention counseling. By this definition, only 10% of state and federal prison
systems and only 5% of the 50 largest jail
systems in the U.S. had a comprehensive
program in 1997.
Beyond this, some may consider a "comprehensive" program to include provision of the means
necessary to effectuate HIV risk reduction.
Perhaps the most commonly advocated such policy is making condoms available to inmates.
However, political considerations have made it
extremely difficult for correctional administrators to
permit condom distribution even though it is hard to
deny that inmates engage in sexual activity within
correctional facilities. As a consequence, only two
state prison systems (Vermont and Mississippi)
and four city/county jail systems (District of
Columbia, New York City, Philadelphia, and San
Francisco) make condoms available to inmates.
This number has not changed since about 1990.
Discharge planning /community linkages
All inmates need more and better services to
help them make successful transitions to the
community, resist relapse to substance use,
and avoid a return to high-risk behavior and
criminal activity. This is especially true for
inmates with HIV disease, who might benefit
from a range of services including continuity
of health care, stable housing, drug treatment, assistance gaining eligibility for benefits, and job training and placement services.
Results of the 1996-1997 CDC/NIJ survey
show that 92% of state/federal prison systems and 76% of the largest city/county jail
systems were providing at least some discharge planning for inmates with HIV and
AIDS. However, further analysis of the survey data reveals that while large percentages of systems were making referrals for
HIV medications (82% of state/federal systems and 66% of city/county systems), drug
treatment (75% and 63%), and for Medicaid
and related benefits (78%, 56%), much
smaller percentages were actually making
appointments for inmates to receive these
services in the community (31% of state/fed

eral systems and 27% of city/county systems
for HIV medications, 22% and 24% for drug
treatment, and 35% and 29% for benefits).
Making a referral can involve simply giving
an individual a list of agencies where they
might apply for services with no further
assistance in actually accessing the services. Making an appointment for a soon-tobe-released inmate with a specific service
provider by no means guarantees that the
person will show up and receive the services, but it represents an additional step in
the process. Geography can be a significant
obstacle to achieving a successful transition.
Exemplary programs in small geographic
locations in Rhode Island4 and Hampden
County, Massachusetts5 successfully provide continuity of services by having local
clinicians provide care both within and outside of the correctional facility. Successful
models in moderate-sized geographic areas,
such as in Connecticut,6 have adopted a
transitional case management model to
overcome problems associated with geography. Such programs are beginning to
demonstrate salutary effects on clinical outcomes as well as on recidivism rates of
inmates participating in them.
Collaboration needed
Correctional systems cannot be expected to
take full responsibility for addressing the
serious public health problem or exploiting
the important public health opportunity represented by the related epidemics of infectious diseases in correctional facilities.
Public health departments, communitybased organizations such as AIDS service
organizations and community-based substance abuse treatment agencies, and other
community-based providers have critical
roles to play as well. There is increasing collaboration among these entities, but there
remain far more opportunities and needs for
working together. There are differences in
philosophy and priority among these organizations, to be sure, but there are also growing examples of overcoming the barriers and
forging successful collaborations to provide
needed services to inmates and releasees
as well as to benefit the public health and
serve the interests of society at large.7

References:
1 The most recent report is Hammett TM, Maruschak L, Harmon P. 1996-1997 Update: HIV/AIDS, STDs, and TB in Correctional Facilities (Washington, July 1999).
Available online at www.ncjrs.org.
2 National Center on Addiction and Substance Abuse. Behind Bars: Substance Abuse and America's Prison Population (New York, 1998), p. 11.
3 Gajewski-Verbanac l, Lewis SM, Chrisman C, Rihn T, Hartman T, Vanscoy GJ. Retrospective analysis of antiretroviral treatment to guidelines in a national correctional base. Abstract #600. Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 26-29, 1999.
4 Vigilante KC, Flynn MM, Affleck PC, Stunkle JC, Merriman NA, Flanigan TP, Mitty JA, Rich JD. Reduction in recidivism of incarcerated women through primary care,
peer counseling, and discharge planning. J Women's Health 1999 Nov 3; 8: 409-15.
5 Conklin TJ, Lincoln T, Flanigan TP. A public health model to connect correctional health care with communities. Am J Public Health 1998 Aug; 88: 1249-50.
6 Altice FL, Khoshnood K. Transitional Case Management as a Strategy for Linking HIV-Infected Prisoners to Community Health and Social Services (Project TLC).
[monograph]. Connecticut Department of Public Health, 1997.
7 Hammett TM. Public health/corrections collaborations: prevention and treatment of HIV/AIDS, STDs, and TB (Washington: National Institute of Justice and Centers
for Disease Control and Prevention, July 1998). Available online at www.ncjrs.org.
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Dear Readers,
This issue of HEPP News marks the last issue of the Millennium! I can think of no better way to end it than to
emphasize the important work presented by Drs. Hammett and Greifinger on the extent of co-morbid medical conditions housed within the U.S. correctional system. This month's HeppiGram depicts some of the information provided. Dr. Hammett reviews for us the burden of HIV and the extent to which current correctional systems have
succeeded in developing comprehensive programs to diagnose, treat and prevent communicable diseases within
our walls.
An interview with Dr. Greifinger and the data he presented at the recent NCCHC meeting in Ft. Lauderdale, FL,
provides insight into the burden of other co-morbid conditions, namely chronic diseases and psychiatric illness.
These data likely represent the minimum burden of disease within the US correctional system as standardized
screening methods were not used to compile the data at selected reporting sites. My hope for these data, which
are to be presented to Congress, is to prompt the federal government to into a more proactive stance in integrating correctional health with our public health system.
Dr. Augustine Mekkum provided an unsolicited opinion piece discussing adherence strategies within correctional
systems. This is one of the most thoughtful pieces on adherence in correctional facilities I've reviewed. However it
is important to recognize that one system does not work for all inmates just as one antiretroviral combination does
not - the operative word is individualize! The unruly nature of medication lines (outside conditions, long lines, poor
confidentiality, etc.) may make "keep on person" the best alternative in some correctional settings. Moreover, are
there not other viable alternatives such as DOT until a person learns how to properly take the medications, is
beyond the initial side effects and has achieved a non-detectable viral load?
Other features this month include graphics showing the prevalence of infectious disease in corrections and antiviral drug interactions. After reviewing this issue, readers should be able to list in order of prevalence which infectious diseases are seen most frequently in correctional systems, describe the burden of mental health disorders,
and identify appropriate antiviral combinations. In next month's issue, we'll bring you Newton Kendig's discussion
of public health and corrections collaborations, as well as a summary of the latest HIV treatment guidelines.
The end of the Millennium (the year for most of us) marks a time for major resolutions. I believe I can speak for
Anne and and new editor Joe Bick by saying that our resolution for the next Millennium is to keep our Newsletter
up-to-date, clearly written, and arriving on time. Our mission for next year is to go international - watch for updates
from Europe, Australia, and the United Kingdom! The entire staff at HEPP News wishes each of you a prosperous
New Year and New Millennium!
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Spotlight: Revealing the Need for Change: An Interview with Robert Greifinger, MD
By HEPP Staff

Robert Greifinger, MD, is a correctional health care consultant and former
chief medical officer for the New York State Department of Correctional
Services. One of Dr. Greifinger's many projects has been to coordinate an
evaluation of the health status of prison and jail inmates for the National
Commission on Correctional Health Care (NCCHC) that was funded by
the NCCHC and the National Institute of Justice (NIJ). The complete
report will be presented to the U.S. Congress in early 2000. Dr. Greifinger
provided HEPP News and an eager audience of correctional health care
providers with a glimpse of the report's findings during his presentation at
the NCCHC in Ft. Lauderdale, FL and during a recent interview.
The goal of this project was to estimate the burden of disease among
soon-to-be-released incarcerated individuals and to make recommendations for public health interventions. The report will provide suggestions to
the federal government for improvements in health care management
within correctional systems.
The report underscores a problem with which correctional providers
should already be familiar: correctional facilities are coping with patients
who have many undiagnosed and untreated health problems and who
have had little access to health care prior to incarceration. Improved management of the many health conditions afflicting inmates will have a dramatic impact on the health care needs of the communities to which they
return. Therefore, Dr. Greifinger feels that the health status of soon-to-bereleased inmates is an important component of the community's health
and deserves to be a targeted public health intervention.
The Extent of the Problem
Dr. Griefinger provided correctional system-reported prevalence projections of various diseases in corrections based on existing survey data.1
Dr. Greifinger emphasizes the fact that these data are projections, and not
based on actual surveys. Data were adjusted for the socioeconomic and
demographic characteristics of inmates. He provided information on the
burden of disease in three categories: communicable diseases, mental
health conditions, and chronic illnesses.
Communicable Disease
Communicable diseases of greatest significance to correctional HIV
providers include Hepatitis B and C, HIV, sexually transmitted infections
(syphilis, gonorrhea, and chlamydia) and airborne diseases such as tuberculosis

Condition

HIV
Syphilis
Chlamydia
Gonorrhea
Hepatitis C (HCV)
Hepatitis B (HBV)
Tuberculosis

Number of
Annual Releases
with Infection* (%)
N~ 8,000,000
98,000-148,000 ^
(1.2-1.8)
558,000 (6.9)
186,000 (2.3)
77,500 (0.9)
1.4 million (17.5)
155,000 (1.9)**
12,000 (0.1)**

Table 1. Communicable Diseases
Key:

% Total
US Patients
with the
Indicated
Condition**
13.1-19.3
N/A^^
N/A^^
N/A^^
29.3-32
12.4-15
35

*Personal communication, Robert Greifinger, December 1999. Percentages calculated by HEPP staff using the reported numbers divided by 8 million, the
approximate number of total annual releases.
**Hammett TM, Harmon P, Rhodes W. The Burden of Infectious Disease Among
Inmates and Releasees from Correctional Facilities. Prepared for the National
Commission on Correctional Health Care-National Institute of Justice "Health
Status of Soon-to-be-Released Inmates" Project, presented at the National
Commission on Correctional Health Care Conference in Fort Lauderdale, FL,
1999.
^These numbers were qualified in Hammett's study as follows: "The large range
in these numbers reflect the fact that their data are based on a combination of testing methodologies which may have different sensitivities. Moreover, sex workers
and others likely at highest risk for STDs may be disproportionately represented
among those released without having been screened. Thus, statistics on jail
intake screening for STDs probably understate the true prevalence of STDs

among people passing through jails."
^^According to Hammett's study, there are no reliable data on the total US prevalence of these three diseases. Thus we did not attempt to calculate these percentages.

Mental Illness
The prevalence of major psychiatric disorders was 50% higher among
incarcerated populations than in the community. However, some mental
illnesses are still under reported in correctional settings. For example,
under-diagnosed or undiagnosed conditions uncovered by this report
included schizophrenia, major depression, and bipolar disorders. The
prevalence of known mental health disorders among inmates currently in
custody is shown in Table 2.
Table 2. Prevalence of Severe Mental illness in Jails and Prisions*

Condition
Schizophrenia
Major Depression
Bipolar Disorder

Jails (%)
1
8-15
1.5-2.6

Prisons (%)
2.3-3.9
14-18
2-4.3

*Personal Communication, Robert Greifinger, December 1999
Compounding the problem, a high percentage of inmates with mental illness also have a co-occurring substance abuse problem. Dr. Greifinger
recommended that correctional providers become familiar with the treatment of patients who carry a "dual diagnosis" (mental illness and substance abuse), the group at highest risk for recidivism.
Chronic diseases
Dr. Greifinger's project also reported on the prevalence of asthma, hypertension and diabetes (see Table 3) among inmates. He said these figures
should cause correctional health providers and policy makers as well as
public health planners to recognize that these conditions are highly prevalent in correctional settings.
Table 3. Prevalence of Chronic Diseases in Prisons and Jails*
*Percentages derived from Greifinger's reported numbers divided by the
Condition
Asthma
Diabetes
Hypertension

Jails
N=592,462

Prisons
N=1,210,034

44,000
12,000
84,000

96,000
32,000
98,000

% of Total US
Patients with
Indicated Condition
9
5
18.5

number of jail and prison inmates as reported in the Bureau of Justice
Statistics Bulletine, Prison and Jail Inmates at Midyear 1995. August
1996, NCJ 161132.
The Recommendations
While the projections may be eye-opening to many, Dr. Greifinger and his
colleagues hope that the report will be a catalyst for changes in correctional health care. He anticipates that the report will make a number of
recommendations to Congress. For example, he suggested that
Congress will need to improve surveillance of communicable diseases,
mental illness and chronic disease in correctional settings. He believes
the report will indicate that Congress should fund a program to develop
the standards for measurement and reporting mechanisms for these diseases. The data might be housed in a national clearinghouse or database,
similar to the HEDIS database for managed care. Dr. Greifinger also suggested that clinical guidelines for prisons and jails may need to be developed to reflect nationally accepted, evidenced based guidelines and have
a measurement of performance against those guidelines. One example
would be to use the National Institutes of Health treatment guidelines for
HIV. In addition, correctional and public health professionals might be
required to become familiar with the guidelines. He thought that the report
would also suggest that a resource be developed to provide correctional
healthcare professionals to updated treatment protocols. Ideally this database would be available on the Internet.
Dr. Greifinger also reported that the following recommendations would be
featured in the report to Congress:
Continued on page 5
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Expert Opinion: Arguments For and Against Directly Observed Therapy for HAART
Augustine C. Mekkam, M.D., R.Ph
Since the introduction of Protease Inhibitors (PI) into the pharmacological
arsenal against the Human Immunodeficiency Virus (HIV), both the quality
and the quantity of life for HIV infected persons has increased. For a
patient to receive these benefits, they must be dedicated to taking any of
the combination of antiretroviral drugs that now make up the so-called
Highly Active Anti-Retroviral Treatment (HAART). Besides the cost of
these medications, the rapid mutation rate of the virus with risks of drug
resistance is reason enough to ensure rigorous adherence to the prescriptions.

regimens coupled with the side effects make it inhumane to require
inmates to visit the medication lines several times each day. They note that
if the goal of DOT were to prevent development of drug resistance, then it
would ultimately achieve the opposite effect by discouraging inmates from
going to the medication lines. Another argument in favor of KOP is that
patients are able to maintain their confidentiality, whereas going to "pill
lines" several times daily reveals their HIV status. On a fiscal note, some
argue that DOT is labor intensive and costly since is requires a nursing staff
administer and note each dose of the HAART given.

In correctional facilities, the issue of adherence has often been the subject
of debate between those who advocate of Directly Observed Therapy
(DOT) and Keep On Person (KOP) medication. In DOT, the inmate-patient
goes to the medication line for each dose of their therapy. While under
KOP, several days (up to one month) supply is dispensed to the inmate to
take at the proper times in the privacy of their cells. In addition to the drug
resistance and cost concerns, there are also the issues of patient confidentiality and self-reliance/responsibility on both sides of the debate.

Both sides of the debate have valid points and only a compromise can
bridge the differences. The need for such a compromise is what led to the
development of a Modified DOT system of HAART administration. Under
this system, HIV positive inmates on HAART go to the medication line each
morning where they are issued individually packed, one-day supplies of
each medication. For the rest of the day, they do not have to return to the
line. Patients self-administer the prescriptions with instructions at the
appropriate times without fear of inadvertently revealing their HIV status to
other inmates. Under this system, medical staffs are able to identify those
inmates who are not showing up for their daily supplies of the medications.
The non-adherent inmates are counseled appropriately. One disadvantage
is the increased time the pharmacy has to spend packaging the medications. However, this cost in pharmacy manpower may be offset by the fact
that the medication line will not need as much staffing in the afternoon and
evenings as compared to the DOT system.

Advocates of DOT often argue that health care staff has the moral responsibility to ensure that all eligible inmate/patients on HAART adhere strictly
to their prescriptions. They often worry that development of resistance is a
public health issue since most of these inmates will eventually parole and
risk infecting others outside the prison. Advocates of DOT are also concerned that many of the inmate/patients have limited education or comprehension of the consequences of poor compliance and hence must be given
extra help in order to attain the maximum benefits of HAART. From a fiscal point of view, it is argued that non-compliant inmates waste expensive
medications and, as such, DOT must be instituted to prevent wasting these
medications.
The opponents of DOT advocate for KOP as the best means of delivering
HAART to inmate-patients. They argue that the complexities of HAART

Although the debate is ongoing, it is believed that Modified DOT will be perceived in due course to be a positive balance which addresses patient confidentiality, ensures compliance monitoring, minimizes the risks of drug
resistance. Above all, Modified DOT makes the inmates active participants
in their care since they would not only be trusted to go to the medication
lines each morning, but would be trusted to remember to take the medicines reliably.

Spotlight: Revealing the Need for Change: An Interview with Robert Greifinger, MD
Continued from page 4
 Establish a national vaccine program to support the implementation of nationally recommended vaccination protocols in correctional settings.
 Promote discussions in ethical decision making among correctional and health authorities to improve their approach to ethical
challenges in corrections.
 Design and promote interventions to reduce obstructions to the
implementation of effective public health programs in correctional
facilities and the community.
 Provide incentives to prisons and jails to expand alcohol and
other drug treatment programs and make these services available
to inmates from admission through release.
 Support research in correctional health care including projects
that emphasize creative and cost-effective options for continuity
of care following release.
 Require correctional systems to adhere to nationally recognized
standards for access, quality of care, quality of service and appropriate credentialing.
The report is also likely to recommend that state and local correctional
agencies provide a smoke free environment, healthy diets, and vaccines

such as Hepatitis B as well as screen pregnant women for these diseases. Moreover, it suggests enhanced collaborations between with state,
local, and other public health entities such as the CDC to analyze potential benefits to the community from early diagnosis of these diseases and
treatment.
According to Dr. Greifinger, this project is the first accurate projection of
the burden of illness among released inmates. "Correctional agencies
have never been charged with the job of protecting the public's health.
What we're saying is it should be part of their job. There should be a clear
public mandate for a correctional institution to work with inmates in terms
of the public's health in three areas: communicable disease, mental illness and chronic disease. I'm hoping this (report) will set a new standard
for the expectations for the medial care of inmates in correctional institutions. This does not compete with current accreditation standards. It
enhances them. We are talking about promoting new opportunities to
improve health care for inmates in areas where it will have a positive
effect on the community."
An audio tape copy of Dr Greifinger's presentation at the NCCHC conference can be obtained from the NCCHC by calling 773-880-1460.

References:
1 Hammett TM, Harmon P, Rhodes W. The Burden of Infectious Disease Among Inmates and Releasees from Correctional Facilities. Prepared for
the National Commission on Correctional Health Care-National Institute of Justice "Health Status of Soon-to-be-Released Inmates" Project, presented
at teh Meeting of the Expert Panel on Communicable Disease, June 14-15 1999, Chicago IL.
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A feature of HEPP News providing concise solutions to correctional HIV-related problems.

Disease Among Incarcerated Populations
The following graphs show infectious disease among incarcerated populations. In 1996, there were estimated to be approximately 16,000 known
HIV infected inmates and does not include the number with undiagnosed HIV infection. HIV prevalence among women and minorities is higher than
among men and whites, respectively, in almost every geographical location. The first is adapted from Hammett TM, and Maruschak, LM. 1996-1997
Update: HIV/AIDS, STD's and TB in Correctional Facilities. July 1999. NCJ 176344. The second is taken from a report given at the Meeting of the
Expert Panel on Communicable Disease "Health of Soon-to-Be-Released Inmates" Project. June 14-15, 1999, Chicago, IL. See the Spotlight, Table
1 for numbers.

Figure 1. Number of Known Cases of HIV
Among Incarcerated Men and Women by State, 1996
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Figure 2. Infectious Disease Among
Incarcerated Populations, 1996
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Figure 2. This figure shows the number of inmates with selected infections. The percentages are the percent of the total US patient population infected with the indicated disease that passed through correctional facilities in 1996.
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Amfar's HIV/AIDS Treatment Directory
A new Web site provides up-to-date information on approved and
experimental HIV therapies for doctors and patients. Located at
www.amfar.org/td, the site includes a searchable database of clinical
trials of experimental treatments. Also on the Web site is a tool that
helps determine the programs that may be best for a patient.

Telephone Numbers:
National Clinicians PEP Hotline:
888. 448. 4911
National HIV Telephone Consultation Service:
800. 933. 3413

Websites:
HIV/AIDS Treatment and Information Services (HIVATIS) webpage
http://www.thebody.com/hivatis/agents/agents01.html
The Bureau of Justice Statistics
http://www.ojp.usdoj.gov/bjs
JAMA HIV/AIDS Information Center
http://www.ama-assn.org/special/hiv
CDC HIV/AIDS Statistics
http://www.cdc.gov/nchstp/hib_aids/stats/hasr1001.pdf
The Corrections Connection
http://www.corrections.com
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News Flashes

UNAIDS and WHO: HIV/AIDS Cases will
Continue to Rise
On December 1, the last World AIDS Day of
this millenium, it seemed appropriate to read
the Lancet's report on the UNAIDS and WHO
predictions for HIV/AIDS in the next century.
At the close of 1999, UNAIDS and WHO estimate that 32.4 million adults and 1.2 million
children will be living with HIV/AIDS. This
past year saw the highest global total of
deaths than any other year of the epidemic:
2.6 million children and adults died from
AIDS in 1999. (Haroon A. Lancet. Nov 27
1999; 354: 1886.)
Peer HIV Education Programs in
Corrections
Three articles in the last issue of the Journal
of the Association of Nurses in AIDS Care
addressed recent findings concerning HIV
care and inmates. A study conducted in a
medium-to-maximum security prison in the
rural South revealed that among 57 newly
incarcerated women there is a high prevalence of domestic violence, three or more
sexual partners (10%) and unprotected sex
during every encounter within the previous
month (72%). Nearly all (97%) reported illicit
drug use as well as sex with an injection drug
user, yet more than half thought they had little or no risk for HIV infection or other sexually transmitted infections. Limited prevention
programs were available for them at the time
of discharge to the community. (Fogel C,
Belyea M. J Assoc Nurses in AIDS Care.
12/99; 10(6) 66).
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Another article in the the same issue advocates peer education for prisoners and
asserts that nurses have a responsibility for
assisting in the design and deployment of
such programs. An ideal peer education program curriculum should carefully select
inmate peers after considering their prison
sentence, the type of offense committed, gender and race/ethnicity. Minimal curriculum
must incorporate a basic understanding
HIV/AIDS, issue of its origins, including conspiracy theory, and facilitate discussion using
commonly used vocabulary terms. (DubikUnruh S. J Assoc Nurses in AIDS Care.
12/99; 10(6) 53.)
An additional article spotlights ACE, a peer
support program for female prisoners with
HIV/AIDS. The AIDS Counseling and
Education Program (ACE) helps with the crisis at Bedford Hills Correctional Facility, New
York State's maximum security prison for
women.
The ACE program educates
inmates about preventing HIV, provides supportive counseling, and uses community
groups to facilitate women's re-enter to society. It also encourages adherence with antiretroviral therapy. (Boudin K, Carrero I, Clark
J. et al. J Assoc Nurses in AIDS Care. 12/99;
10(6) 90.)
OSHA/CDC Urge the use of Safety Needles
The CDC has urged health facilities to use
specially designed safety needles to protect
health care workers (HCWs) from accidental
needle stick injuries. The notice comes just

weeks after the Occupational Safety and
Health Administration authorized its inspectors to issue citations to health care facilities
that fail to use the safer needles. The FDA
has already approved 50 safety needles and
syringes, including those that have
retractable needles, syringes with protective
sheaths and vaccine injectors that use pressure rather than a needle to deliver medication. It is estimated that the use of safety needles would reduce the injuries by 80% among
the 600,000 annual needlestick injuries to
HCWs. Unfortunately, only 15% of hospitals
currently use safety needles. Three states
(CA, MD, TN) currently legislate mandatory
use of safety needles and 20 others are considering similar legislation. Cost is cited as a
barrier to safety syringe use which cost to
$.25 compared to $.06 per routine needle.
(Press release, November 23, 1999. Full article available at:
http://www.cdc.gov/od/oc/media/pressrel/r99
1123.htm). Editor's note: OSHA's standards
presumably apply in the correctional setting.
HIV Plus: Prison Issue
HIV Plus, the largest-circulation HIV magazine in the US, has produced a special comprehensive issue on prisons. HIV Plus is distributed free to AIDS service providers. For a
single copy, fax request to 212.334.9227 or
call 212.625.0897. For bulk orders (25+) call
212.334.9119 ext.42. Also available at
www.aidsinfonyc.org/hivplus.

SUBSCRIBE TO HEPP NEWS
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Continued from October: Part 2: Drug Interactions: Protease Inhibitors and Non-nucleoside Reverse Transcriptase Inhibitors
Effect of Drug on Levels (AUCs)/Dose (Adapted from HIVATIS webpage: www.thebody.com/hivatis/agents/agents01.html)
Drug Affected

Ritonavir

Saquinavir *

Nelfinavir

Amprenavir

Nevirapine

Indinavir
(IDV)

Levels: IDV up 25X
Dose: Limited
data for IDV 400
mg bid, RTV 400
mg bid, or IDV
600 mg bid RTV
200 mg bid, or
IDV 800 mg bid,
RTV 100 mg bid

Levels: IDV no
effect;

Levels:
IDV up 50%;
NFV up 80%

Levels: APV up
33% (750 mg
bid)
IDV down 38%

Levels: IDV down Levels: IDV up
28%
40%
NVP no effect
Dose: IDV 600
Dose: Standard mg q 8h

Levels: IDV down
31%

Forthcoming
No
Data
data to be presented at the
Retrovirus
Conference
February 2000.

Levels:
RTV down 11%

Levels: RTV up
70%

NVP no effect

Dose: No data

Levels: RTV up
18%
EFV up 21%

Levels:
SQV up 3-5x;
NFV up 18% #

Levels: APV
down 32%
SQV up 20%

Levels:
SQV down 25%

Dose: Standard
NFV ; FTV 1200
tid

Dose: No Data

NVP no effect
Dose: No Data

Levels: No
change in APV
NFV up 15%
Dose: standard

Levels: NFV up
10%
NVP no effect
Dose: standard

Ritonavir
(RTV)

Saquinavir
(SQV)

Nelfinavir
(NFV)

SQV up 4-7x#
Dose: higher
doses may be
antagonistic^

Dose: limited
data for IDV 1200 Dose: No Data
mg bid NFV
May need to up
1250 mg bid
IDV dose

Levels: RTV no
effect;
SQV up 20x**#

Levels: RTV no
effect; NFV up
1.5x
Dose: limited
Dose: Invirase or data for RTV 400
Fortovase 400
mg bid NFV 500mg bid ** RTV:
750 mg bid
400 mg bid
see under SQV
column

See under NFV
column

See under NFV
column

Nevirapine
(NVP)

see under NVP
column

see under NVP
column

see under NVP
column

No Data - May
reduce APV
levels

Delavirdine
(DLV)

see under DLV
column

see under DLV
column

see under DLV
column

No Data - May
increase APV
levels

Delavirdine

Dose:
Standard

Efavirenz

Dose: IDV
1000mg
q 8h

Dose: RTV 600
mg bid (500 mg
bid for
intolerance)

Levels: SQV up
5x;** DLV no
effect
Dose: Fortovase
800 mg tid, DLV
standard (monitor
transaminase
levels)

Levels: SQV
down 62%
EFV down 12%
co-administration
not
recommended

Levels: NFV up
2x
DLV down 50%
Dose: no data
(monitor for
neutropenic
complications)

Levels: NFV up
20%

No Data

No Data

No Data__

Dose: Standard

No Data

APVEFV
no data, may
reduce APV

* Several drug interaction studies have been completed with saquinavir given as Invirase or Fortovase. Results from studies conducted with Invirase
may not be applicable to Fortovase.
** Conducted with Invirase.
# Conducted with Fortovase (FTV).
^ A test tube study published in the July issue of the Journal of Infectious Diseases showed that low doses of saquinavir and indinavir appeared to
work together to inhibit HIV replication. However, as the doses increased the two drugs appeared to work against each other, counteracting their
combined antiviral effects against the virus. The scientists involved with the study were concerned that using these two protease inhibitors together
could increase the chances of the virus developing resistance to both drugs.

Subscribe to HIV Inside

A new quarterly newsletter addressing HIV-management issues specific to correctional care.
If you are interested in receiving this free publication, please fill out the form below. In addition to receiving HIV Inside, this contact information will be entered into an HIV-management database, allowing additional education materials to be forwarded.
Name ________________________________________________________________________________________
Title

________________________________________________________________________________________

Agency/Facility ________________________________________________________________________________
Address________________________________________________________________________
City ______________________________________________ State ______________________ Zip __________
Phone ____________________________________________ Fax ______________________________________
Fax back to Brendan Maney at World Health CME at 212.481.8534
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Self-Assessment Test for Continuing Medical Education Credit

Brown University School of Medicine designates this educational activity for 1 hour in category 1 credit toward the AMA Physicians
Recognition Award. To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each
of the questions. A minimum of 70% of the questions must be answered correctly. This activity is eligible for CME credit through
January 31, 2000. The estimated time for completion of this activity is one hour and there is no fee for participation in this activity.
1. Hepatitis C prevalence in corrections is what fraction of the
total US population infected with HCV?
a) 1/8
b) 1/6
c) 1/5
d) 1/4
e) 1/3
2. According to Robert Greifinger, the most prevalent communicable diseases in correctional facilities include the following.
Rank these diseases in order of prevalence in prisons.
a) Hepatitis B
b) Hepatitis C
c) HIV
d) sexually transmitted diseases (syphilis, gonorrhea, and
chlamydia)
e) airborne diseases such as tuberculosis
ranking: highest __ __ __ __ __ lowest
3. Which of the following statements is false?
a) Schizophrenia is more prevalent in corrections than
bipolar disorders.
b) Overall, the presence of major psychiatric disorders is
50 percent higher in corrections populations than in the
community.
c) Prevalence of mental illness in prisons is about twice
that in jails.
4. Review the following drug combinations, and select the choice
(a to e) that is most accurate. Which of the following antiretroviral combinations, in combination with other antiretroviral agents,
might be appropriate for use in patients with HIV infection?
I. Ritonavir 200 mg BID + Indinavir 800mg BID (4 pills
twice daily)
II. Nelfinavir 1250 mg BID + Fortovase 1200 mg BID (11
pills twice daily)
III. Fortovase 1200 mg TID + Efavirenz 600 mg QHS (21
pills per day in divided doses)
IV. Indinavir 1200 mg BID + Nelfinavir 1250 mg BID (8
pills twice daily)

Choose from among the following:
a) Only one of the choices above is accurate.
b) Only I and III
c) Only II and IV
d) Only three of the choices above are accurate
e) All of the above are accurate
5. Ritonavir may increase the level of multiple antivirals. When
combined with Ritonavir, which of the following antivirals require
a dosage adjustment when give in combination with RTV?
a) Saquinavir
b) Nelfinavir
c) Nevirapine
d) a and b
e) all of the above
6. Which of the following statements is false?
a) Peer education is a cost effective HIV prevention strategy.
b) The majority of prisoners with substance abuse disorders receive drug treatment within the correctional setting.
c) The majority of prisoners with HIV infection are men.
d) Hepatitis C is the most prevalent of infectious disease
within corrections.
e) Though most prison systems make preferred combination therapy available, as many as one-third do not
receive recommended combinations.
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1. Please evaluate the following sections with respect to:
main article
secondary
article
HEPPigram
updates
save the date

educational value
5 4 3 2 1
5 4 3 2 1

clarity
5 4 3 2 1
5 4 3 2 1

5 4 3 2 1
5 4 3 2 1
5 4 3 2 1

5 4 3 2 1
5 4 3 2 1
5 4 3 2 1

2. Do you feel that HEPP News helps you in your work?
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4. How can HEPP News be made more useful to you?
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